Suven gets patent for CNS drug in Europe, Israel
City-based biopharmaceutical company, Suven Life Sciences Limited, has been granted one product patent each by Europe and Israel corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with nero-degenerative diseases.
​Hyderabad: City-based biopharmaceutical company, Suven Life Sciences Limited, has been granted one product patent each by Europe and Israel corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with nero-degenerative diseases. The patents are valid trough 2030 and 2029, respectively.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life Chief Executive Officer Venkat Jasti said on Tuesday.
With these new patents, Suven has a total of 23 patent from Europe and 12 from Israel. “These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licenced at various phases of clinical development like Phase-I or Phase-II,” Suven said.
